ADCendo
ADCs for underserved cancer treatment.
What is the issue to solve?
Underserved cancers lacking effective treatment options for patients.
What’s their solution?
Developing antibody-drug conjugates (ADCs) to treat underserved cancers by targeting cancer cells and minimizing toxicity to normal tissue.
Who is their product for?
Oncologists specializing in underserved cancers, pharmaceutical companies, cancer researchers, patients.
Competitors
AI Disclaimer
We have generated these company profiles using AI and feeding it the companies website. Because of that we cannot guarantee the accuracy and we welcome any feedback, we will promptly change any inaccuracies.
Thank you!